Comparison of different classes of drugs for Management of Acute Coronary Syndrome (ACS): A brief communication
Mudasir Maqbool (Department of Pharmaceutical Sciences, University of Kashmir)
Tawseef Ahmad Hajam (Department of Pharmaceutical Sciences, University of Kashmir)
Muhammad Abrar Khan (National Institute of Pharmaceutical Education and Research)
Mehrukh Zehravi (Department of Clinical Pharmacy Girls Section, Prince Sattam Bin Abdul Aziz University Alkharj)
Abstract
Acute coronary syndrome (ACS) is a class of conditions consisting of NSTEMI (non-ST-elevated myocardial infarction), STEMI (ST-elevated myocardial infarction), unstable angina, ranging from myocardial ischaemic states, as well as there is usually a mismatch with respect to both blood supply and blood demand marked by chest pain. Indian patients with ACS have a higher STEMI score than patients of established countries'. Since most of these patients were poor, they were less likely to receive adequate therapy and had a higher death rate of 30 days. In India, ACS patients appear to be young from low socioeconomic backgrounds and have higher ST-elevated MI rates than do patients of established countries'. In India, patients get late medical treatment and inadequate access to proven therapies. Hypertension, hyperlipidemia, diabetes, obesity, cigarette use and a family history of atherosclerotic disease are important risk factors attributed to ACS. Most of the general therapy for ACS focuses on reducing myocardial ischemia and pain suppression. Because of the time dependence of the condition, the onset of signs and arrival at the hospital for the treatment of ACS is very important. This time gap between the onset of symptoms and hospital appearance is larger in India relative to western countries. This paper will concentrate on ACS management and a brief on comparative study of various groups of drugs available with regard to clinical trials and guidelines, respectively.
- keywords
- Management, Acute coronary syndrome, therapies, Angina
참고문헌
Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–STElevation Myocardial Infarction—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiology, 2007;50(7):652-726.
Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction)developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiology, 2007;50(7):e1-e157
Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, et al. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J, 2016;178:176-184.
Chen Z. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (London, England), 2005; 366: 1607-1621.
Cheng, JW. Updates in antiplatelet agents used in cardiovascular diseases. Journal of cardiovascular pharmacology and therapeutics, 2013;18(6):514-524.
Collins R, Peto R, Flather M, Parish S, Sleight P, Conway M, et al. ISIS-4-A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardialinfarction. Lancet (London, England), 1995;345(8951):669-685.
Comin J. & Kallmes D. Clopidogrel (plavix). American journal of neuroradiology, 2011;32(11):2002-2004.
Dargie, H. The CAPRICORN Investigators: Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001;357(9266):1385-1390.
della Sopravvivenza nell’Infarto, S. Effects of reviparin, a lowmolecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA, 2005;293: 427-436.
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS. & Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. The Lancet, 2000;355(9219):1936-1942.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA, 2011;306(24):2673-2683.
Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, et al. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Eur Heart J Acute Cardiovasc Care, 2017;6(2):155-163.
Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiology, 2012;60(7):645-681.
Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensinconverting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 1995;333(25):1670-1676.
Korff S, Katus HA & Giannitsis E. Differential diagnosis of elevated troponins. Heart, 2006;92(7):987-993.
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (London, England), 2010;376(9748),1233-1243. doi: 10.1016/s0140-6736(10)61088-4
Miocardico, GIplSdSnI. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet (London, England), 1994;343(8906):1115-1122.
Moser DK, Kimble LP, Alberts MJ, Alonzo A, Croft JB, Dracup K, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation, 2006;114(2):168-182.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiology, 2013;61(4):e78-e140.
Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM & Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. The American journal of cardiology, 2013;111(4):521-525.
Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine, 1992;327(10):669-677.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
Smith JN, Negrelli JM, Manek MB, Hawes EM & Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. Journal of the American Board of Family Medicine, 2015;28(2):283-293.
Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Athanasiou A, Moris D & Politou M. The role of prasugrel in the management of acute coronary syndromes: a systematic review. Eur Rev Med Pharmacol Sci, 2017;21(20):4733-4743.
Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J of the American College of Cardiology, 2014;63(25 Part B):2889-2934.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR. & White, HD. Third universal definition of myocardial infarction. Glob Heart, 2012;7(4):275-295.
Verheugt FW. Acute coronary syndromes: drug treatments. The Lancet, 1999;353:s20-s23.
Wang D, Yang XH, Zhang JD, Li RB, Jia M & Cui XR. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord, 2018;18(1):018-0948.
Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA, 1997;278(23):2093-2098.
White HD & Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation, 1998; 97(16):1632-1646.doi: 10.1161/01.cir.97.16.1632
Yusuf S. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med, 2001;345:494-502
- 다운로드 수
- 조회수
- 0KCI 피인용수
- 0WOS 피인용수